Info

Opexa Therapeutics, Inc. (Opexa or Opexa Therapeutics) is a biopharmaceutical company developing autologous cellular therapies to treat several illnesses, including multiple sclerosis (MS), rheumatoid arthritis (RA), and diabetes. These therapies are based on the Company’s T-cell and adult stem cell technologies. Opexa Therapeutics’ lead product, Tovaxin, is a T-cell based therapeutic vaccine for MS. Tovaxin is in a Phase IIb clinical trial. Initial Phase I/II open-label human trials show that T-cell vaccination (TCV) appears to safely induce immune responses that deplete and regulate MRTCs. The Company holds worldwide license for the intellectual property rights and research results of an autologous T-cell vaccine for RA from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. Opexa’s RA T-cell vaccination (TCV) technology allows the isolation of these pathogenic T-cells from synovial fluid drawn from a patient.(Source: 10-K)